Other
Buruli Ulcer Disease
4
Pipeline Programs↗
1
Active Trials↗
3
Companies Involved↗
Buruli ulcer disease is an early-stage landscape with 4 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Sanofi, AbbVie. 3 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Analysis
Trial Status
2
clinical trials
Recruiting1 · 50%
Completed1 · 50%
Clinical Trials
Trial Activity
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy
Recruiting·FFundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)·Phase 2·NCT05169554·140 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)